Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Journal of Neural Transmission

Volumn 117, Issue 3, 2010, Pages 343-347

  Janik, P ^a   Kwiecinski, H ^a   Sokolowska, B ^b   Niebroj Dobosz, I ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Erythropoietin; Serum

Indexed keywords

ERYTHROPOIETIN;

ADULT; AGE DISTRIBUTION; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BULBAR PARALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEUROPROTECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SPINE DISEASE;

ADULT; AGE FACTORS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; HUMANS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77952431030     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0354-2     Document Type: Article

References (34)

1. Arcasoy MO (2008) The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141:14-31
2. Brettschneider J, Widl K, Ehrenreich H, Riepe M, Tumani H (2006) Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neurosci. Lett 404:347-351. (Pubitemid 44108436)
3. Brettschneider J, Widl K, Schattauer D, Ludolph AC, Tumani H (2007) Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neurosci Lett 416:257-260 (Pubitemid 46483860)
4. Brines ML, Ghezzi P, Keenan S, Angelo D, de Larenolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the bloodbrain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531.
5. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Disease (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293-299
6. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Grasso G, Corica F, Frisina N (2002) Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci (Lond) 103:275-282
7. Buemi M, Lacquaniti A, Maricchiolo G, Bolignano D, Campo S, Cernaro V, Sturiale A, Grasso G, Buemi A, Allegra A, Donato V, Genovese L (2009) Regenerative medicine: does erythropoietin have a role? Curr Pharm Des 15:2026-2036
8. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, Caputi AP, Buemi. M (2000) Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 401:349-356 (Pubitemid 30608719)
9. G93A transgenic mice. Brain Res 1016:272-280
10. Ehrenreich H, Hasselblat M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505 (Pubitemid 36337492)
11. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M (2004) Erythropoietin, novel approaches to neuroprotection in human brain disease. Metab Brain Dis 19:195-208 (Pubitemid 39361181)
12. Felgenhauer K (1995) The filtration concept of the blood-brain barrier as basis for the differentiation of CSF proteins. In: Greenwood J et al (eds) New concepts of a blood-brain barrier. Plenum, London, pp 209-217
13. Gene S, Koroglu TF, Gene K (2004) Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 22:105-119
14. Ghezzi S, Del Bo R, ScarlatoC M, Nardini M, Carlesi C, Prelle A, Corti S, Maneuso M, Briani C, Siciliano G, Muri L, Bresolin N, Comi GP (2009) Is erythropoietin gene a modifier factor in amyotrophic lateral sclerosis? Neurobiol Aging 30:842-884
15. Grignashi G, Zennaro E, Tortarolo M, Calvaresi N, Bendotti C (2007) Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotroph Lateral Scler Other Motor Neuron Dis 8:31-35 (Pubitemid 46322937)
16. Grunfeld JF, Barhum Y, Blodheim N, Jm Rabey, Melamed E, Offen D (2007) Erythropoietin delays disease onset in an amyotrophic lateral, sclerosis model. Exp Neurol 204:260-263 (Pubitemid 46350729)
17. Just N, Moreau C, Lassalle P, Gösset P, Perez T, Brunaud-Danel V, Wallaert B, Destèe A, Defebvre L, Tonnel AB, Devos D (2007) High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromusc Disord 17:169-173 (Pubitemid 46298697)
18. Juul SE, Anderson DK, Li Y, Christensen RD (1998) Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 43:40-49 (Pubitemid 28069166)
19. Juul SE, Stallings SA, Christensen RD (1999) Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 46:543-547
20. Keswani SC, Buldanliogiu U, Fischer A, Reed N, Polley M, Liang H, Zhou C, Jack C, Leitz GJ, Hoke A (2004) A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 56:815-826 (Pubitemid 39578445)
21. Koh SH, Kim Y, Kim HY, Cho GW, Kim KS, Kim SH (2007) Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SODI mouse model of ALS by preventing motor neuron death and inflammation. Eur J Neurosci 25:1923-1930 (Pubitemid 46581743)
22. Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, Antozzi C, Ciano C, Beretta P, Caldiroli D, Ghelma F, Ferrara G, Ghezzi P (2009) Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 29:1-6
23. Liao ZB, Zhi XG, ShiOH He ZH (2008) Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. Eur J Neurol 15:140-149
24. Marti HH (2004) Erythropoietin and the hypoxic brain. J Exp Biol 207:3233-3242
25. Marti HH, Gassmann M, Wenger RH, Kvietikova I, MorgantiKossmann MC, Kossmann T, Trentz O, Bauer C (1997) Detection of erythropoietin in human liquor intrinsic erythropoietin production in the brain. Kidney Int 51:416-418 (Pubitemid 27088152)
26. Martinez-Estrada OM, Rodriquez-Milan E, Gonzalez de Vicente E (2003) Erythropoietin protects the in-vitro blood-brain barrier VEGF-induced permeability. Eur J Neurosci 18:2538-2544
27. Mennini T, de Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L (2006) Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 12:153-160 (Pubitemid 44646344)
28. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral, cortical, and erythropoietin prevents glutamate-induced neuronal death. Neuroscience 76:1.05-116 (Pubitemid 26407940)
29. Nakamura T, Ebihara I, Shimada N, Koide H (1998) Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients. Am J Med Sci 31:199-201 (Pubitemid 28125609)
30. Riviere M, Meininger V, Zeisser P, Munsat T (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with Riluzole. Arch Neurol 55:526-528 (Pubitemid 28182699)
31. Sakanaka M, Wen TC, Matsuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protect neurons from ischemic damage. Proc Natl Acad Sci USA 3:4635-4640
32. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heuman R, CeramiA Ehrenreich H, Ghezzi P (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98:4044-4049 (Pubitemid 32249895)
33. Thompson EJ (1988) The CSF proteins: a biochemical approach. Elsevier Sci Publ BV, Amsterdam, pp 67-85
34. Widl K, Brettschneider J, Schattauer D, Süssnuth S, Huber P, Ludolph AC, Tumani H (2007) Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease. Neurochem Res 32:1163-1168 (Pubitemid 46817465)